Sofosbuvir for previously untreated chronic hepatitis C infection.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  New England Journal of Medicine

• Publication date

  2013-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1214853PMID 23607594
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

  2013cited by this paper
• Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

  2013cited by this paper
• How to optimize HCV therapy in genotype 1 patients with cirrhosis

  2013cited by this paper
• Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

  2013cited by this paper
• New Pharmacotherapy for Hepatitis C

  2012cited by this paper
• Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.

  2012cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Hepatitis C virus infection in USA: an estimate of true prevalence

  2011cited by this paper
• PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication

  2010cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009cited by this paper
• Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

  2007cited by this paper
• The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

  2006cited by this paper
• Global epidemiology of hepatitis C virus infection.

  2005cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• Gastric adenocarcinoma and kidney transplantation

  1998cited by this paper
• Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase.

  1991cited by this paper

• Recent Progress in Structures and Functions of Hepatitis C Virus NS3/4A Proteins.

  2026cites this paper
• Heterogeneity in Risk and Implications for Hepatitis C Reinfection in People Who Inject Drugs in England

  2025cites this paper
• A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)

  2025cites this paper
• EU’s Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD)

  2025cites this paper
• Trends in substance use over 31 years in a large methadone maintenance treatment (MMT) clinic in Israel.

  2025cites this paper
• Post-recurrence Survival After Liver Transplantation for Hepatocellular Carcinoma.

  2025cites this paper
• Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?

  2025cites this paper
• Chronicity of disease mandates quality-of-life prioritization - a role for digital health and patient-reported outcome measures.

  2025cites this paper
• Pan-viral efficacy profile of ribavirin: quantitative potency and safety landscape across virus families

  2025influential citation
• In silico analysis of bioactive compounds of Nigella sativa as potential inhibitors of NS5B RdRp protein involved in the pathogenesis of hepatitis C virus

  2025cites this paper
• Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals

  2024cites this paper
• Expanding the liver donor pool worldwide with hepatitis C infected livers, is it the time?

  2024cites this paper
• Renal Manifestations of Chronic Hepatitis C: A Review

  2024cites this paper
• Antiviral drug recognition and elevator-type transport motions of CNT3

  2024cites this paper
• Second Generation Catalytic Enantioselective Nucleophilic Desymmetrization at P(V): Improved Generality, Efficiency and Modularity.

  2024cites this paper
• Research status and hotspots in the field of endoplasmic reticulum stress and liver disease: A bibliometric study

  2024cites this paper
• Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

  2024cites this paper
• Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review

  2024cites this paper
• Hepatitis C Elimination in Egypt: Story of Success

  2024cites this paper
• β-d-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus.

  2024cites this paper
• Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.

  2024cites this paper
• Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

  2024cites this paper
• Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances

  2024cites this paper
• Effectiveness of second-generation direct-acting antivirals in patients infected with hepatitis c virus and factors associated with a nonsustained virological response

  2024influential citation
• Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis

  2024cites this paper
• Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies

  2024cites this paper
• Implementation of a novel framework for hepatitis C diagnosis and treatment in an academic health system.

  2024cites this paper
• What is disease modification and is this concept even helpful?

  2024cites this paper
• Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications.

  2024cites this paper
• A new fluorescence probe for sofosbuvir analysis in dosage form and spiked human plasma.

  2024cites this paper
• Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study

  2024cites this paper
• Development of a General Organophosphorus Radical Trap: Deoxyphosphonylation of Alcohols.

  2024cites this paper
• Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection

  2024cites this paper
• A systematic PCR record‐based re‐call of HCV‐RNA‐positive people enables re‐linkage to care and HCV elimination in Austria — The ELIMINATE project

  2024cites this paper
• Sofosbuvir (+) daclatasvir (+) ribavirin in Egyptian patients with hepatitis C virus: Therapeutic outcomes and the prognostic role of natural killer cells.

  2024cites this paper
• Reflecting on a Decade of Sofosbuvir Use for Hepatitis C Virus Treatment.

  2024cites this paper
• Assessment of ubiquitin specific Peptidase-18 gene in peripheral blood of chronic hepatitis C patients treated with direct-acting antiviral drugs

  2024cites this paper
• Elimination of hepatitis C in the Middle East: a narrative review of the efficacy of direct-acting antiviral therapies

  2023cites this paper
• Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients

  2023cites this paper
• Mathematical processing of absorption as green smart spectrophotometric methods for concurrent assay of hepatitis C antiviral drugs, Sofosbuvir and Simeprevir: application to combined pharmaceutical dosage forms and evaluation of the method greenness

  2023cites this paper
• in Children

  2023cites this paper
• Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir

  2023cites this paper
• Hepatitis C antibody test frequencies and positive rates in Switzerland from 2007 to 2017: a retrospective longitudinal study.

  2023cites this paper
• Formulation and Evaluation of Chitosan Based Sofosbuvir Solid Lipid Nanoparticles

  2023cites this paper
• QSPR Analysis of Diverse Drugs Using Linear Regression for Predicting Physical Properties

  2023cites this paper
• Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects

  2023cites this paper
• A 10-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China

  2023cites this paper
• Combining Treatment for Chronic Hepatitis C with Opioid Agonist Therapy is an Effective Microelimination Strategy for People Who Inject Drugs with High Risk of Non-Adherence to Antiviral Therapy

  2023cites this paper
• Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

  2023cites this paper
• Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

  2023cites this paper
• An end is in sight: a perspective on PCR as an endpoint for Chagas disease treatment trials

  2023cites this paper
• Genotype 4 hepatitis C virus-a review of a diverse genotype.

  2023cites this paper
• Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy

  2023cites this paper
• Therapeutic potential of salicylamide derivatives for combating viral infections

  2023cites this paper
• Old age as a risk factor for liver diseases: Modern therapeutic approaches.

  2023cites this paper
• Impact of Treatment of Chronic HCV Patients by Direct Acting Antiviral Drugs (DAADs) on COVID -19 Disease Frequency and Severity

  2023cites this paper
• Structural biology of voltage-gated calcium channels

  2023cites this paper
• Non-noble metal-catalyzed cross-dehydrogenation coupling (CDC) involving ether α-C(sp3)–H to construct C–C bonds

  2023cites this paper
• Evolving challenges with long‐term care of liver transplant recipients

  2023cites this paper
• Comparative outcomes of direct-acting antiviral treatment in patients with HIV-Hepatitis C co-infection: insights from a single center experience in Colombia.

  2023cites this paper
• Novel sofosbuvir derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective

  2023cites this paper
• Viral Fitness, Population Complexity, Host Interactions, and Resistance to Antiviral Agents.

  2023cites this paper
• Deciphering Drug Targets and Actions with Single-Cell and Spatial Resolution.

  2023cites this paper
• Cost Minimization Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants.

  2023cites this paper
• Identification of TMEM53 as a novel SADS-CoV restriction factor that targets viral RNA-dependent RNA polymerase

  2023cites this paper
• Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease.

  2023cites this paper
• Hépatites virales

  2022cites this paper
• The scientific progress and prospects of hepatitis C research from 2013 to 2022.

  2022cites this paper
• Small molecules in the treatment of COVID-19

  2022cites this paper
• Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels.

  2022cites this paper
• Discontinuing Directly Acting Antivirals During Hepatitis C Treatment: Highlighting an Infrequent but Hostile Event.

  2022cites this paper
• Temporal trends of waitlistings for liver transplantation in Italy: The ECALITA (Evolution of IndiCAtion in LIver transplantation in ITAly) registry study.

  2022cites this paper
• Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful

  2022cites this paper
• Innovative Approaches to Engaging Homeless and Marginally Housed Patients in Care: a Case Study of Hepatitis C

  2022cites this paper
• Concordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial

  2022cites this paper
• Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity

  2022cites this paper
• Breakthroughs in hepatitis C research: from discovery to cure

  2022cites this paper
• Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients

  2022cites this paper
• Saffron extract attenuates Sofosbuvir‐induced retinal neurodegeneration in albino rat

  2022cites this paper
• An efficient, catalyst and solvent free Staudinger phosphite reaction for the synthesis of phosphoramidates under mild conditions

  2022cites this paper
• Case study of hepatitis C virus control in Egypt: impact of access program

  2022cites this paper
• Carbohydrate-based drugs launched during 2000−2021

  2022cites this paper
• SARS-CoV-2 Mutant Spectra at Different Depth Levels Reveal an Overwhelming Abundance of Low Frequency Mutations

  2022cites this paper
• Hepatitis B and C: Neglected Infectious Diseases among Syrian Refugees in Lebanon

  2022cites this paper
• The Effect of Sofosbuvir Administration on Albino Rats’ Buccal Mucosa (Histological and immunochemical study)

  2022cites this paper
• Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C.

  2022cites this paper
• Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients

  2022cites this paper
• The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition

  2022cites this paper
• The effect of hepatitis C—associated premature deaths on labour productivity losses in Spain: a ten-year analysis

  2022cites this paper
• Why Molnupiravir Fails in Hospitalized Patients

  2022cites this paper
• Interleukin-18 signaling system links to agitation in severe mental disorders.

  2022cites this paper
• Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome

  2022cites this paper
• Integrating hepatitis C virus screening of baby boomers at a community hospital emergency department

  2022cites this paper
• Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

  2022cites this paper
• Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa

  2022cites this paper
• Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy

  2022cites this paper
• Insights on the disruption of glucose metabolism and hepatic insulin resistance induced by hepatitis C virus

  2022cites this paper
• Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

  2022cites this paper
• The cellular poly(rC)-binding protein 2 prevents the early steps of hepatitis C virus virion assembly

  2022cites this paper
• Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.

  2021cites this paper